Using MRI-guided radiation therapy for treating certain cancers
Official title: Clinical Onboard Utilization of Image Guided Radiation Therapy With Magnetic Resonance (CONFIRM): A Master Protocol
Run by Brigham and Women's Hospital · NCT04368702 · Data updated 2026-11-12
This study is testing if using MRI to guide radiation therapy along with chemotherapy can safely and effectively treat patients with gastric and breast cancers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | May 1, 2021 |
| Main results expected | June 18, 2029 |
| Study ends | June 18, 2029 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT04368702 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with confirmed gastric or breast cancer requiring radiation therapy.
✕Probably not a fit
Patients with severe claustrophobia, anxiety, or those unable to undergo an MRI will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the safety and feasibility of using magnetic resonance imaging (MRI) to guide radiation therapy combined with chemotherapy for patients with gastric and breast cancers. The study utilizes the MRIdian Linear Accelerator to adapt radiation delivery in real-time, targeting the precise location of tumors. Participants will undergo screening, treatment evaluations, and follow-up visits, while their experiences will be documented through questionnaires. This is a Phase I/II feasibility study, marking the first examination of this MR-guided radiation approach at the institution, although it has been used at other centers.
Why it matters
Potential benefit: If successful, this approach could lead to more precise and effective radiation treatments for patients with gastric and breast cancers.
How similar studies have gone: Other institutions have successfully utilized MRI-guided radiation therapy, indicating potential for positive outcomes in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed malignancy requiring radiation * Age 18 years of older * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) * Ability to understand and the willingness to sign a written informed consent document. * Any further criteria listed in the specific disease site cohort Exclusion Criteria * History of allergic reactions attributed to gadolinium-based IV contrast \-- Note: If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility * Severe claustrophobia or anxiety * Participants who cannot undergo an MRI * Any other exclusion criteria listed in the specific disease site cohort
Where it's running
-
Brigham & Women's Hospital
Boston, Massachusetts, United States Recruiting -
Dana Farber Cancer Institute
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Raymond Mak, MD — Dana-Farber Cancer Institute
- Study coordinator: Raymond Mak, MD
- Email: rmak@partners.org
- Phone: 6177328651
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prehabilitation before high-risk cancer surgery
This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.
-
Evaluation of a new robotic surgical system for major gastrointestinal and urologic surgeries
This study is testing a new robotic surgery system to see if it can safely and effectively help patients with major gastrointestinal and urologic conditions like colorectal and prostate cancer.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Using a new imaging agent to detect various cancers
This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
Investigating HER3-DXd for advanced solid tumors
This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.